Eloralintide

Overview

Eloralintide (Lilly code LY3841136) is an investigational long-acting amylin receptor agonist developed by Eli Lilly for overweight and obesity. Public chemistry records include PubChem CID 175663130 (formula C₂₀₁H₃₁₉N₄₉O₆₅S₂; MW 4526; CAS synonym 2883634-40-8). In clinical protocols it has been given once weekly subcutaneously.

Peer-reviewed phase 1 and phase 2 human data are available. Multiple phase 3 studies were listed as recruiting as of the 2026-10-07 dossier cut. No FDA or EMA approval was identified.

Identity and mechanism

Published discovery work describes preferential agonism at human AMY1R versus CTR and AMY3R, reduced conditioned taste avoidance versus cagrilintide in rat models, and weight loss driven by fat-mass reduction in diet-induced obese rats, with monkey PK support (Briere et al., Mol Metab 2025, PMID 41109426).

Amylin signalling contributes to satiety and gastric emptying; that pharmacology is shared at a high level with other amylin analogues, but receptor selectivity claims for eloralintide should be tied to the cited in-vitro profile, not generalised from the class.

Clinical development (selected)

Key human results (peer-reviewed)

Phase 1 SAD (within NCT05295940; Briere et al., 2025)

Forty-eight healthy participants (mean BMI 27.5) received single subcutaneous doses in a 0.04–12 mg range. Adverse events were mostly mild; gastrointestinal events were uncommon. At week 4, reported mean weight change was about −2.5% and −4.4% at the 4 mg and 12 mg dose levels versus +0.6% with placebo (study estimates — not an authorised regimen).

Phase 1b MAD / proof-of-concept (Bhattachar et al., 2026)

One hundred participants (mean BMI 32.6) received once-weekly fixed doses (1.2 / 3 / 6 / 12 mg cohorts) for 12 weeks without dose escalation. Plasma half-life was about 13.9–15.8 days with roughly dose-proportional PK. Week-12 least-squares mean percent weight change ranged from about −2.6% to −11.3% across dose groups. Reported GI rates in the paper were relatively low (diarrhoea 10%, nausea 8%, vomiting 4%) — an indirect contrast with typical incretin profiles, not a head-to-head proof of better tolerability.

Phase 2 (Billings et al., Lancet 2025; NCT06230523)

Multicentre US trial (n=263, 46 sites) over 48 weeks, with fixed weekly arms (1 / 3 / 6 / 9 mg) and escalation arms (6→9 mg; 3→9 mg) versus placebo. Primary endpoint: percent weight change at week 48 (efficacy estimand). Approximate published means were about −9 / −12 / −18 / −20 / −20 / −16% across active arms versus about −0.4% placebo. Nausea and fatigue were among the more common adverse events; GI events were more frequent with higher starting doses. Treat secondary reports of “near-placebo GI with 3→6→9 titration” as secondary to the peer-reviewed Lancet primary paper.

Phase 3 outcomes were not available at the dossier cut — studies were still recruiting.

Claims vs evidence

Related pages

• Pramlintide — approved short-acting amylin analogue (US)
• Cagrilintide — long-acting amylin/CTR-family agonist
• CagriSema — fixed combination of cagrilintide + semaglutide
• Petrelintide, Zenagamtide — other next-generation amylin-pathway candidates

What this page intentionally omits

• Any self-use dose, titration schedule, or reconstitution protocol
• Assertions of regulatory approval or clinical superiority over incretins or cagrilintide without comparative trials